Table 1.

Body mass variation. Body mass variation (final body mass − initial body mass/initial body mass × 100) of Swiss mice infected with the Colombian strain and treated with Theracurmin and benznidazole for 30 days. Data expressed as mean ± SEM.

Uninfected and Untreated (%)	Theracurmin (%)	T. cruzi (%)	T.cruzi + Theracurmin (%)	T. cruzi + Benznidazole (%)
12.94 ± 0.96	9.718 ± 1.5	0.7850 ± 2.5 *	1.995 ± 3.4 *,#	3.072 ± 4.2 *,#

* p < 0.05 when compared to the uninfected/untreated animals. ^# p < 0.05 when compared to the T. cruzi-infected group.